Cancer therapeutics

Breast cancer cell
#Breast cancer #Cancer therapeutics #Clinical trials #Intensity Therapeutics #intratumoural cancer therapies #Tumours

Phase II triple-negative breast cancer trial restarts

Intensity Therapeutics has administered INT230-6 in the INVINCIBLE-4 Study in Switzerland. The clinical biotechnology company is focused on the discovery and development of novel intratumoural cancer therapies that are designed to kill tumours and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology. The trial (NCT06358573) analyses… Read More

#News

#AACR #AACR 2025 #Cancer #Cancer research #Cancer therapeutics #Oncology

Insight from AACR 2025

The American Association of Cancer Research (AACR) Annual Meeting took place from 25-30 April at the McCormick Place Convention Center in Chicago, US. DDW’s Megan Thomas looks at key announcements, presentations and breakthroughs that took place. Presidential commentary On Sunday 27 April, attendees were welcomed at the Opening Ceremony by… Read More

#Cancer Research #Exclusive Content

#Cancer research #Cancer therapeutics #Financing #Small molecules #Vivace Therapeutics

Financing secured for cancer drug targeting the Hippo pathway

Vivace Therapeutics has announced the closing of $35 million Series D financing to support the company’s small molecule cancer therapeutics targeting the Hippo pathway. The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. Proceeds will support… Read More

#Cancer Research #News

Medical professional examining mammogram
#Breast cancer #Cancer therapeutics #Drug repurposing #ETH Zurich #Oncology

Digoxin prevents breast cancer metastases in a new study

The active ingredient digoxin, a substance found in foxglove, reduces the number of cells in clusters of breast cancer cells circulating in the blood, new research has found.  These clusters are responsible for the formation of metastases in other organs. The smaller the clusters, the fewer metastases… Read More

#Cancer Research #Editor's Choice #News

#Cancer therapeutics #Cancer vaccine #CAR-T #Oncology #Radiopharmaceuticals

New DDW Highlights episode: 10 February 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following World Cancer Day on 4 February, the news round-up this week focuses on… Read More

#News

#Cancer therapeutics #Cancer vaccine #CAR-T #Oncology #Radiopharmaceuticals

This week in drug discovery (3-7 February) 

News round-up for 3-7 February by DDW Senior Digital Content Editor Diana Spencer. Following World Cancer Day on 4 February, the news round-up this week focuses on new approaches to the treatment of cancer, including radiopharmaceuticals, programmable cell depletion and preventative vaccines. The top stories:… Read More

#News

#Antibody drug conjugate (ADC) #Cancer therapeutics #Cancer treatment #Interview #Oncology

Reducing cancer side effects through targeted therapies

Harry Palmer, Royal Commission of 1851 Industrial Fellow and PhD at University of Strathclyde, shares with DDW’s Megan Thomas how antibody-drug conjugates (ADCs) are revolutionising cancer treatment by offering targeted therapies with improved efficacy and reduced side effects, while addressing challenges in their development and paving the way for future… Read More

#Cancer Research #Exclusive Content

Cancer cell
#Cancer research #Cancer therapeutics #Oncology #World Cancer Day

World Cancer Day: Five key cancer drug discoveries of the year so far

For World Cancer Day, Diana Spencer collates five most significant oncology research advances so far in 2025. An AI drug discovery breakthrough Results of an in vivo mouse colorectal cancer model study have shown a 60% life extension for Oxford Drug Design’s first-in-class approach against multiple… Read More

#Cancer Research #News #Trending News

#Cancer therapeutics #Cancer vaccine #Immunotherapy #mRNA-based vaccines #Oncology

A deep dive into cancer vaccines

Megan Thomas explores the innovation and opportunity for cancer vaccines with Dr Alexander Zehnder, CEO of CureVac, and Dr Chris Haqq, Chief Medical Officer of Elicio Therapeutics. It could be argued that Covid-19 gave us a boost to start making headway in cancer vaccines. Between the acceleration of mRNA vaccine… Read More

#Cancer Research #Exclusive Content

Cancer tumour
#Cancer therapeutics #Clinical trials #Immunology #Society of Immunotherapy for Cancer (SITC) #Storm Therapeutics

New clinical data on first-in-class METTL3 inhibitor 

Storm Therapeutics has presented promising data from its Phase I clinical study evaluating its METTL3 RNA methyltransferase inhibitor, STC-15, at the Society of Immunotherapy for Cancer (SITC) 39)th Annual Meeting, held in Houston, US, from 6-10 November 2024.    The Phase I clinical study… Read More

#News

#Cancer drug targets #Cancer therapeutics #Cancer treatment #Oncology

New DDW Highlights podcast: 22 October 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we are halfway through Breast Cancer Awareness Month, our news highlights this week… Read More

#News

#Cancer drug targets #Cancer therapeutics #Cancer treatment #Oncology

This week in drug discovery (14-18 October) 

News round-up for 14-18 October by DDW Senior Digital Content Editor Diana Spencer. As we are halfway through Breast Cancer Awareness Month, our news highlights this week focus on studies that could advance the treatment of cancer in the future, including a new understanding of cancer drug… Read More

#News

Cancer metastasis
#Cancer therapeutics #Clinical trials #ESMO #Events #Oncology

The latest breakthroughs in cancer research

The European Society for Medical Oncology (ESMO) Congress 2024 took place in Barcelona, Spain, 13-17 September 2024, and featured some significant breakthroughs in cancer drug discovery. NIAGARA Phase III trial AstraZeneca presented positive results from its NIAGARA Phase III trial, a global study to evaluate the… Read More

#Cancer Research #News #Trending News

Two scientists working in a research laboratory
#Cancer research #Cancer therapeutics #Funding #Innovate UK #Oncology

Cancer drug discovery projects receive £12 million

Twenty-three companies will benefit from a share of £12 ($15.8) million from the Innovate UK Cancer Therapeutics programme. The Cancer Therapeutics programme focuses on developing life-changing cancer treatments, including immunotherapies and vaccines. It also supports projects addressing unmet medical needs for treating childhood and young persons’… Read More

#Business & Investment #Cancer Research #News